Specialized pro-resolving mediators (SPMs) generated when aspirin irreversibly acetylates COX-2 at serine-530, converting it from a pro-inflammatory prostaglandin-synthesizing enzyme to a producer of 15R-HETE lipid intermediates. These intermediates are further processed by 5-LOX to yield aspirin-triggered resolvins (AT-RvD1, AT-RvE1) and protectins (AT-PD1), which actively promote inflammatory resolution without immunosuppression. AT-resolvins are R-epimers (15R stereochemistry) rather than the S-epimers produced endogenously, but retain equal or greater pro-resolution potency.
Think of COX-2 as a factory machine that normally stamps out inflammatory alarm bells (prostaglandins). When aspirin arrives, it's like a mechanic who permanently adjusts the stamping die—not shutting the machine down, but changing what it produces. Now the same factory line produces "all-clear" signals instead of alarms. The raw material (DHA or EPA) enters the same COX-2 machine, but because aspirin has modified it, the output is flipped to 15R-HETE instead of pro-inflammatory mediators. This 15R-HETE then travels to the next production station (5-LOX), which finishes the job by converting it into aspirin-triggered resolvins—specialized "cleanup crew coordinators" that tell neutrophils to stop arriving, tell macrophages to start eating debris, and tell the whole inflammation site to actively wind down. It's not just stopping the fire alarm; it's actively dispatching the cleanup team with specific instructions.
Acetylation and Enzymatic Switching:
- Low-dose aspirin (75-100 mg daily) enters circulation and acetylates COX-2 at Ser530 (irreversible covalent modification)
- Acetylated COX-2 loses its ability to produce Prostaglandins (PGE2, PGI2) but gains oxygenase activity at C15 position
- Instead of producing pro-inflammatory eicosanoids, acetylated COX-2 generates 15R-HETE (hydroxyeicosatetraenoic acid) from Arachidonic acid or 18R-HEPE from EPA
Biosynthetic Cascade:
- From DHA pathway:
- Aspirin-acetylated COX-2 + DHA → 17R-HDHA (17R-hydroxy-DHA)
- 5-LOX (on neutrophils/macrophages) converts 17R-HDHA → AT-RvD1, AT-RvD2, AT-RvD3, AT-RvD4
- From EPA pathway:
- Aspirin-acetylated COX-2 + EPA → 18R-HEPE
- 5-LOX converts 18R-HEPE → AT-RvE1, AT-RvE2
- Protectin pathway:
- 17R-HDHA (from acetylated COX-2) → AT-PD1 (aspirin-triggered neuroprotectin D1) via lipoxygenase processing
Receptor Signaling and Resolution Actions:
- AT-RvD1 binds to:
- ALX/FPR2 receptor on neutrophils/macrophages → inhibits NF-κB → ↓ pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
- GPR32 receptor (human-specific) → ↑ cAMP → blocks neutrophil chemotaxis and transmigration
- AT-RvE1 binds to:
- ChemR23 (ERV1 receptor) → enhances macrophage Efferocytosis (apoptotic cell clearance)
- BLT1 receptor (antagonist action) → blocks leukotriene B4 signaling, preventing neutrophil recruitment
Resolution Mechanisms:
- Neutrophil regulation: AT-resolvins block L-selectin expression and integrin activation → neutrophils stop adhering to endothelium → cessation of infiltration
- Macrophage reprogramming: AT-RvD1 stimulates M2 macrophages phenotype → ↑ Efferocytosis genes (MerTK, CD36) → clearance of apoptotic neutrophils without secondary necrosis
- Cytokine switching: ↓ IL-1β, TNF-α, IL-6 while ↑ IL-10 → active resolution environment
- Antimicrobial enhancement: AT-resolvins upregulate antimicrobial peptides (LL-37, β-defensins) → resolution without infection risk
graph TD
A[Low-dose Aspirin 75-100mg] --> B[Acetylates COX-2 at Ser530]
B --> C["Acetylated COX-2 + DHA/EPA"]
C --> D[17R-HDHA or 18R-HEPE]
D --> E[5-LOX processing]
E --> F[AT-RvD1/D2/D3/D4 or AT-RvE1/E2]
F --> G[Binds ALX/FPR2, GPR32, ChemR23]
G --> H[Neutrophil stop signal]
G --> I["Macrophage efferocytosis ↑"]
G --> J["Pro-inflammatory cytokines ↓"]
H --> K[Resolution without immunosuppression]
I --> K
J --> K
C --> L[Lipoxygenase pathway]
L --> M[AT-PD1 neuroprotectin]
M --> N[Neuroprotection in stroke/AD models]
Cardiovascular Benefits Beyond COX Inhibition:
Aspirin's cardiovascular protective effects are not solely due to antiplatelet action via COX-1 inhibition—the generation of AT-resolvins explains why aspirin reduces atherosclerotic plaque inflammation and stabilizes vulnerable plaques. Other NSAIDs that inhibit COX without acetylating it (ibuprofen, naproxen) lack this pro-resolution mechanism and show inferior cardiovascular outcomes. This aligns with the metamodel 5 principle that stopping inflammation (COX-1 inhibition) is not the same as promoting resolution (AT-resolvin generation).
Omega-3 Dependency:
AT-resolvin production requires adequate tissue DHA and EPA levels (omega-3 index >8% ideal). Patients taking low-dose aspirin without sufficient omega-3 intake produce minimal AT-resolvins, limiting the resolution benefit. This represents an evolutionary mismatch—modern diets deficient in marine omega-3s (hunter-gatherer intake ~3-4g/day vs. modern ~150mg/day) create substrate limitation. Clinical strategy: combine 75-100mg aspirin with 2-3g EPA+DHA daily to maximize AT-resolvin synthesis.
Chronic Inflammatory Conditions:
AT-resolvins have shown clinical benefit in:
- Periodontal disease: AT-RvD1 reduces bone loss and promotes regeneration (clinical trials show improved pocket depth and attachment levels)
- Inflammatory bowel disease: AT-resolvins accelerate mucosal healing and reduce relapse rates
- Atherosclerosis: reduces macrophage content in plaques and promotes efferocytosis of apoptotic foam cells
- Alzheimer's disease: AT-PD1 shows neuroprotective effects, reduces microglial activation, enhances amyloid-β clearance
NSAID vs. Aspirin Distinction:
High-dose aspirin (>300mg) or competitive COX inhibitors (ibuprofen) can paradoxically block AT-resolvin synthesis by preventing COX-2 acetylation. This contributes to the "NSAID paradox" where chronic NSAID use suppresses acute inflammation but promotes chronic non-resolving inflammation. In cPNI practice, this informs the choice: low-dose aspirin (75-100mg) for pro-resolution effects, avoid chronic ibuprofen/naproxen which lack resolution-promoting capacity.
Selfish Immune System Context:
AT-resolvins exemplify how the immune system can be "coached" toward resolution rather than suppressed. Unlike immunosuppressive drugs (corticosteroids, biologics), AT-resolvins enhance antimicrobial defenses while resolving inflammation—they satisfy both the immune system's infection-fighting agenda and the organism's tissue-repair agenda. This makes them ideal for conditions where immune suppression is risky (infections, cancer) but resolution is needed.
Clinical Thresholds:
- Effective aspirin dose for AT-resolvin synthesis: 75-100mg/day (higher doses may paradoxically reduce production)
- Required omega-3 index: >8% for optimal substrate availability
- AT-RvD1 potency: active at picomolar to nanomolar concentrations (10-100× more potent than parent resolvins)
- Timing: aspirin-mediated COX-2 acetylation occurs within 30-60 minutes; AT-resolvin peak production occurs 4-6 hours post-ingestion during active inflammatory phase
- Low-dose aspirin (75-100mg) acetylates COX-2 at Ser530, converting it from pro-inflammatory prostaglandin synthesis to 15R-HETE production
- AT-RvD1 is 10-100× more potent than endogenous resolvin D1 at promoting resolution at ALX/FPR2 receptors
- AT-resolvins are R-epimers (15R stereochemistry) vs. S-epimers produced endogenously, but equally or more bioactive
- Production requires both aspirin AND adequate tissue DHA/EPA—omega-3 index >8% ideal
- Other NSAIDs (ibuprofen, naproxen) do NOT generate aspirin-triggered resolvins; they lack the acetylation mechanism
- AT-PD1 (aspirin-triggered protectin D1) shows neuroprotective effects in stroke, Alzheimer's, and traumatic brain injury models
- AT-resolvins actively enhance antimicrobial defenses (↑ LL-37, β-defensins) while resolving inflammation—no immunosuppression
- High-dose aspirin (>300mg) or competitive COX inhibitors can block AT-resolvin synthesis by preventing COX-2 acetylation
- AT-resolvins bind ALX/FPR2, GPR32, and ChemR23 receptors to stop neutrophil infiltration and enhance macrophage efferocytosis
- Clinical cardiovascular benefits of aspirin partly mediated by AT-resolvin-driven plaque stabilization and reduced vascular inflammation
- AT-RvD1 accelerates periodontal disease resolution in clinical trials (improved pocket depth, attachment gain)
- Aspirin-triggered resolvins represent lipid mediator class switching—from pro-inflammatory prostaglandins to pro-resolution mediators via single enzymatic modification
- aspirin — acetylates COX-2 enabling switch from prostaglandin to AT-resolvin production
- COX-2 — aspirin-acetylated COX-2 produces 15R-HETE precursors instead of pro-inflammatory prostaglandins
- COX-2 acetylation — irreversible modification at Ser530 that converts COX-2 from pro-inflammatory to pro-resolution enzyme
- Resolvins — AT-resolvins are R-epimer versions of endogenous S-epimer resolvins, equally or more potent
- DHA — essential substrate for AT-RvD1, AT-RvD2, AT-RvD3, AT-RvD4 synthesis via aspirin-acetylated COX-2
- EPA — substrate for AT-RvE1 and AT-RvE2 synthesis via aspirin-modified COX-2 pathway
- Specialized pro-resolving mediators (SPMs) — AT-resolvins are subset of SPM family, distinguished by aspirin-dependent synthesis
- 5-LOX — converts 15R-HETE intermediates (from acetylated COX-2) into final AT-resolvin products
- inflammation — AT-resolvins actively drive inflammatory resolution phase without immunosuppression
- inflammatory resolution — AT-resolvins promote active resolution via neutrophil stop signals, macrophage efferocytosis, cytokine switching
- neutrophils — AT-resolvins block neutrophil chemotaxis, adhesion, and transmigration via ALX/FPR2 and GPR32 receptors
- Macrophages — AT-resolvins enhance M2 macrophage polarization and efferocytosis of apoptotic cells
- Efferocytosis — AT-RvD1 upregulates MerTK and CD36 on macrophages to clear apoptotic neutrophils without secondary necrosis
- ALX-FPR2 receptor — primary receptor for AT-RvD1; mediates anti-inflammatory and pro-resolution signaling
- NSAID — competitive COX inhibitors (ibuprofen, naproxen) do NOT generate AT-resolvins, only aspirin does via acetylation
- Omega-3 fatty acids — adequate omega-3 tissue levels (omega-3 index >8%) required as substrate for AT-resolvin synthesis
- cardiovascular disease — aspirin's cardioprotective effects partly due to AT-resolvin-mediated plaque stabilization and reduced vascular inflammation
- Lipid mediator class switching — aspirin-mediated COX-2 acetylation exemplifies switch from pro-inflammatory (PGE2) to pro-resolution (AT-resolvins) mediators
- Protectins — AT-PD1 (aspirin-triggered protectin D1) is DHA-derived neuroprotective SPM synthesized via acetylated COX-2
- chronic inflammation — deficient AT-resolvin production (low omega-3s, chronic NSAID use) contributes to non-resolving inflammatory states
- IL-10 — AT-resolvins upregulate IL-10 production while downregulating IL-1β, TNF-α, IL-6 for resolution microenvironment
- NF-κB — AT-RvD1 binding to ALX/FPR2 inhibits NF-κB activation, reducing pro-inflammatory cytokine transcription
- Atherosclerosis — AT-resolvins promote macrophage efferocytosis in atherosclerotic plaques, reducing necrotic core and stabilizing lesions
- Periodontal disease — AT-RvD1 accelerates resolution of periodontal inflammation and promotes bone regeneration in clinical studies
- Alzheimer's Disease — AT-PD1 reduces neuroinflammation, enhances microglial amyloid-β clearance, protects synaptic function in AD models
- COX-1 — aspirin also acetylates COX-1 (antiplatelet effect) but AT-resolvin synthesis specifically requires COX-2 acetylation
- Arachidonic acid — can be converted by acetylated COX-2 to 15R-HETE, though DHA/EPA pathways yield more potent AT-resolvins